Magnesium%252525252525252520sulphate

# Magnesium Sulphate ## Overview Magnesium is a divalent cation essential for neuromuscular transmission and enzymatic reactions. For clinical administration, it is primarily used as an electrolyte replacement or a pharmacological agent for stabilization or smooth muscle relaxation. ## Primary Indications * **Hypomagnesemia:** Correction of severe deficiency. * **Eclampsia/Preeclampsia:** Prophylaxis and treatment of seizures. * **Torsades de Pointes:** First-line agent for polymorphic ventricular tachycardia. * **Acute Asthma Exacerbation:** Adjunctive therapy for severe, refractory cases. ## Adult Dosing * **Hypomagnesemia:** 1–4 g IV/IM. Common protocol: 2 g infused over 10–60 minutes. Severe cases may require 4–8 g over 12–24 hours. * **Eclampsia/Preeclampsia:** 4–6 g IV loading dose over 15–20 minutes, followed by 1–2 g/hour continuous infusion. * **Torsades de Pointes/Cardiac Arrest:** 1–2 g IV push (over 5–20 minutes). * **Acute Severe Asthma:** 2 g IV administered over 20 minutes. ## Pediatric Dosing * **Hypomagnesemia:** 25–50 mg/kg/dose IV/IM (max 2 g/dose). May repeat every 6 hours for 3–4 doses. * **Acute Asthma Exacerbation:** 25–50 mg/kg IV once (max 2 g). * **Note:** Always verify individual institutional protocols as pediatric dosing varies significantly based on acuity and indication. ## Dose Adjustments * **Renal Impairment:** Reduce dose and frequency in patients with impaired renal function (CrCl <30 mL/min). Monitor serum magnesium levels frequently to prevent accumulation. * **Elderly:** Use lower starting doses due to decreased renal clearance. ## Contraindications * Myasthenia gravis (may exacerbate muscle weakness). * Heart block or myocardial damage. * Severe renal impairment (absolute contraindication for high-dose bolus). * Use with caution in patients with hypermagnesemia or hypocalcemia. ## Adverse Effects * **Common:** Flushing, hypotension, bradycardia, diaphoresis. * **Severe (Toxicity):** Loss of deep tendon reflexes (DTRs), respiratory depression, heart block, cardiac arrest. * **Antidote:** Calcium gluconate (1 g IV) to reverse respiratory depression or magnesium toxicity. ## Key Drug Interactions * **Neuromuscular Blocking Agents:** Potentiates effect; risk of prolonged paralysis. * **Aminoglycosides:** Additive neuromuscular blockade. * **Digitalis Glycosides:** Increased risk of cardiac arrhythmias if magnesium is administered rapidly. * **CNS Depressants:** Enhanced sedative effects. ## Monitoring * **Clinical:** Check DTRs (patellar reflex should be present), respiratory rate (>12 breaths/min), and urine output (>30 mL/hr). * **Laboratory:** Serum magnesium levels (goal depends on indication; target 2.0–4.0 mg/dL for cardiac indications). * **ECG:** Monitor for PR interval prolongation or QRS widening. ## Clinical Pearls * **Administration:** Rapid IV push can cause profound hypotension and asystole in non-arrest scenarios. Always observe infusion rates. * **Asthma:** Magnesium acts as a smooth muscle relaxant; it is not a bronchodilator in the traditional beta-agonist sense. * **Eclampsia:** Seizure prophylaxis should continue for at least 24 hours postpartum. * **Dosing Uncertainty:** Dosing is highly protocol-dependent. Always refer to local hospital guidelines or specific hospital pharmacy policies. *** *Disclaimer: This information is for educational purposes and does not substitute for clinical judgment or established institutional protocols. Always verify dosing, contraindications, and drug interactions against current, peer-reviewed prescribing information (e.g., Lexicomp, Micromedex) before administration.*